Venture-backed ProNAi Therapeutics files to raise $86 mln on Nasdaq
ProNAi Therapeutics Inc, a Vancouver-based clinical-stage oncology company, has filed with the U.S. Securities and Exchange Commission (SEC) to launch an initial public offering on the Nasdaq Global Market under the ticker symbol "DNAI." According to the SEC filing, the company is seeking to raise up to US$86.2 million. Established in 2004, ProNAi is developing and commercializing a new class of therapies through its DNA interference platform for patients with cancer and hematological diseases. Last year, the company secured US$59.5 million in Series D financing, which was led by U.S. venture capital firm Vivo Capital and was joined by existing investors. It has a research facility in Plymouth, Michigan.
15 June 2015•2 mins read
